NCT03467984View on ClinicalTrials.gov

A Study to Evaluate the Safety and Immunogenecity of LBVE(Multivalent Pneumococcal Conjugate Vaccine) in Healthy Infants

PHASE2CompletedINTERVENTIONAL
Enrollment

230

Participants

Timeline

Start Date

May 25, 2018

Primary Completion Date

October 5, 2018

Study Completion Date

March 27, 2019

Conditions
Pneumococcal Infection
Interventions
BIOLOGICAL

LBVE

Multivalent pneumococcal conjugate vaccine be administered by Intramuscular injection into the thigh

BIOLOGICAL

Prevnar13

13-valent pneumococcal conjugate vaccine be administered by Intramuscular injection into the thigh

Trial Locations (1)

07795

LG chem, Seoul

Sponsors

Lead Sponsor

LG Chem
All Listed Sponsors
lead

LG Chem

INDUSTRY

NCT03467984 - A Study to Evaluate the Safety and Immunogenecity of LBVE(Multivalent Pneumococcal Conjugate Vaccine) in Healthy Infants | Biotech Hunter | Biotech Hunter